Holen Sie sich die Stockscreener-App
90.45
3.98%
3.46
Handel nachbörslich:
90.83
0.38
+0.42%
Schlusskurs vom Vortag:
$86.99
Offen:
$88.75
24-Stunden-Volumen:
8.97M
Relative Volume:
1.65
Marktkapitalisierung:
$133.82B
Einnahmen:
$15.91B
Nettoeinkommen (Verlust:
$1.79B
KGV:
110.30
EPS:
0.82
Netto-Cashflow:
$1.89B
1W Leistung:
+2.23%
1M Leistung:
+2.70%
6M Leistung:
+21.17%
1J Leistung:
+66.45%
1-Tages-Spanne:
$88.50
$91.08
1-Wochen-Bereich:
$86.01
$91.08
52-Wochen-Spanne:
$53.93
$91.08
Boston Scientific Corp Stock (BSX) Company Profile
Firmenname
Boston Scientific Corp
Sektor
Branche
Telefon
508-683-4000
Adresse
300 BOSTON SCIENTIFIC WAY, MARLBOROUGH, MA
Vergleichen Sie BSX mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
| BSX | 90.45 | 133.82B | 15.91B | 1.79B | 1.89B | 0.82 |
| ABT | 117.36 | 202.64B | 41.22B | 5.77B | 6.49B | 2.94 |
| SYK | 389.40 | 150.72B | 21.97B | 3.59B | 3.21B | 6.74 |
| MDT | 87.59 | 112.98B | 32.58B | 3.93B | 5.15B | 2.71 |
| EW | 69.89 | 40.52B | 6.60B | 4.16B | 490.10M | 2.34 |
Boston Scientific Corp Stock (BSX) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2024-02-01 | Hochstufung | Mizuho | Neutral → Buy |
| 2023-07-19 | Eingeleitet | Robert W. Baird | Outperform |
| 2023-06-30 | Eingeleitet | CL King | Buy |
| 2023-05-30 | Fortgesetzt | Morgan Stanley | Overweight |
| 2023-03-29 | Eingeleitet | UBS | Buy |
| 2022-12-22 | Eingeleitet | Mizuho | Neutral |
| 2022-12-20 | Fortgesetzt | Citigroup | Buy |
| 2022-10-18 | Eingeleitet | Barclays | Overweight |
| 2022-10-12 | Eingeleitet | Jefferies | Buy |
| 2022-07-06 | Eingeleitet | Wolfe Research | Outperform |
| 2022-05-27 | Hochstufung | Needham | Hold → Buy |
| 2022-04-13 | Fortgesetzt | Truist | Buy |
| 2022-03-02 | Fortgesetzt | BofA Securities | Buy |
| 2021-12-10 | Eingeleitet | RBC Capital Mkts | Outperform |
| 2021-05-26 | Herabstufung | Needham | Buy → Hold |
| 2021-05-25 | Eingeleitet | Barclays | Overweight |
| 2021-04-15 | Eingeleitet | Atlantic Equities | Overweight |
| 2020-09-17 | Eingeleitet | Truist | Buy |
| 2020-09-11 | Eingeleitet | Wolfe Research | Peer Perform |
| 2020-04-22 | Herabstufung | SVB Leerink | Outperform → Mkt Perform |
| 2020-04-01 | Hochstufung | Goldman | Neutral → Buy |
| 2020-03-05 | Eingeleitet | Citigroup | Buy |
| 2020-02-13 | Eingeleitet | Goldman | Neutral |
| 2020-02-06 | Fortgesetzt | BTIG Research | Buy |
| 2019-12-30 | Bestätigt | Cowen | Outperform |
| 2019-12-19 | Herabstufung | Needham | Strong Buy → Buy |
| 2019-09-05 | Fortgesetzt | JP Morgan | Overweight |
| 2019-09-03 | Fortgesetzt | Barclays | Overweight |
| 2019-05-13 | Hochstufung | Evercore ISI | In-line → Outperform |
| 2018-11-28 | Eingeleitet | UBS | Buy |
| 2018-10-16 | Eingeleitet | Barclays | Overweight |
| 2018-10-02 | Bestätigt | Morgan Stanley | Overweight |
| 2018-09-07 | Bestätigt | Needham | Strong Buy |
| 2018-09-04 | Hochstufung | Jefferies | Hold → Buy |
| 2018-07-06 | Bestätigt | Needham | Strong Buy |
| 2018-06-27 | Eingeleitet | Bernstein | Outperform |
| 2018-04-26 | Bestätigt | Needham | Strong Buy |
Alle ansehen
Boston Scientific Corp Aktie (BSX) Neueste Nachrichten
Boston Sci study shows Watchman Flx better OPTION than DOAC - BioWorld Online
Boston Scientific Completes $3.7B Acquisition of Axonics - Orange County Business Journal
Boston Scientific stock soars to all-time high of $89.33 - Investing.com
Boston Scientific stock soars to all-time high of $89.33 By Investing.com - Investing.com Canada
Here's Why We Think Boston Scientific (NYSE:BSX) Might Deserve Your Attention Today - Yahoo Finance
Boston Scientific acquires Axonics - Medical Buyer
Boston Scientific reports outcomes from trial of LAAC device - Yahoo Finance
Boston Scientific to Acquire Cortex - Today's Medical Developments
Boston Scientific's WATCHMAN FLX Shows Superior Bleeding Risk Reduction in 3-Year Study | BSX Stock News - StockTitan
Boston Scientific (BSX) Completes Acquisition of Axonics - GuruFocus.com
Boston Scientific Corp. stock underperforms Friday when compared to competitors - MarketWatch
Boston Scientific put volume heavy and directionally bearish - TipRanks
Boston Scientific Closes $3.7B Deal for Axonics - MPO-mag
Boston Scientific Closes Acquisition of Axonics, Inc. - Quantisnow
Boston Scientific Closes Acquisition of Axonics, Inc. – Company Announcement - Financial Times
Boston Scientific closes $3.7B Axonics deal after lengthy review - Yahoo Finance
Boston Scientific Corp. stock underperforms Thursday when compared to competitors - MarketWatch
SoniVie Names Axonics' Raymond Cohen as Chairman Following $3.7B Boston Scientific Deal | BSX Stock News - StockTitan
Boston Scientific Co. (NYSE:BSX) Shares Bought by Huntington National Bank - MarketBeat
Investing in Boston Scientific (NYSE:BSX) three years ago would have delivered you a 113% gain - Yahoo Finance
Boston Scientific Corp. stock outperforms competitors on strong trading day - MarketWatch
Urology Devices Market to Surpass Market Valuation of USD 61.62 Billion by 2031 | SkyQuest Technology - Benzinga
Boston Scientific EVP John Sorenson sells $2.68m in stock - Investing.com
Boston Sci charges ahead with AVANT GUARD PFA trial - BioWorld Online
Boston Scientific To Present At 2024 UBS Global Healthcare Conference; Webcast At 10:15 AM ET - Nasdaq
Boston Scientific resumes enrolment in pulsed field ablation trial - Yahoo Finance
BSXBoston Scientific Corp. Latest Stock News & Market Updates - StockTitan
Boston Scientific Corporation (BSX): Among the Best Low Volatility Stocks to Invest In Now - Insider Monkey
Boston Scientific Corporation (BSX): A Hot Growth Stock to Buy According to Hedge Funds - Insider Monkey
Van ECK Associates Corp Has $5.06 Million Stock Holdings in Boston Scientific Co. (NYSE:BSX) - MarketBeat
8 Hot Growth Stocks To Buy According to Hedge Funds - Insider Monkey
Boston Scientific stock soars to all-time high of $88.81 - Investing.com
We Think Boston Scientific's (NYSE:BSX) Profit Is Only A Baseline For What They Can Achieve - Yahoo Finance
Petri Dish: Boston Scientific resumes atrial fibrillation trial; Seaport hires CFO - The Business Journals
Boston Scientific CEO sells shares worth $13.8 million By Investing.com - Investing.com Canada
Boston Scientific CEO sells shares worth $13.8 million - Investing.com
Boston Scientific Corp. stock rises Thursday, still underperforms market - MarketWatch
Boston Scientific (BSX) Resumes AVANT GUARD Clinical Trial for A - GuruFocus.com
Boston Scientific resumes AVANT GUARD trial - Investing.com
Kidney Stone Management Market Forecast Report, 2024-2032Cook Group, Richard Wolf, Boston Scientific, and Dornier MedTech Actively Engaged in M&As to Increase Share - Yahoo Finance
Boston Scientific Resumes AVANT GUARD Clinical Trial - TipRanks
Boston Scientific Corp. stock rises Wednesday, still underperforms market - MarketWatch
Boston Scientific Corp. stock rises Tuesday, still underperforms market - MarketWatch
Boston Scientific to Speak at Conference - Baystreet.ca
Boston Scientific to Participate in the 2024 UBS Global Healthcare Conference – Company Announcement - Financial Times
Boston Scientific to bolster cardiac ablation portfolio with Cortex acquisition - Medical Device Network
Heritage Investors Management Corp Sells 7,684 Shares of Boston Scientific Co. (NYSE:BSX) - MarketBeat
Johnson & Johnson, Boston Scientific least shorted stocks in S&P 500 healthcare sector for Feb-end - MSN
Boston Sci to acquire Cortex, expand AF portfolio - BioWorld Online
Boston Scientific EVP Wendy Carruthers sells $588,876 in stock - Investing.com
Boston Scientific EVP Wendy Carruthers sells $588,876 in stock By Investing.com - Investing.com UK
Finanzdaten der Boston Scientific Corp-Aktie (BSX)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.17%
0.07%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):